VYGLEA

Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), frontotemporal dementia, cognitive impairment of aging, pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, chronic neuropathic pain, peripheral neuropathy, pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, Obsessive Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, adjunctive use